Global Breast Cancer Market Assessment, By Type [Ductal Carcinoma In Situ, Invasive Ductal Carcinoma, Lobular Carcinoma In Situ, Invasive Lobular Cancer, Triple Negative Breast Cancer, Inflammatory Breast Cancer, Metastatic Breast Cancer, Breast Cancer During Pregnancy, Other Types], By Treatment Type [Surgery, Radiation Therapy, Chemotherapy, Hormonal therapy, Targeted Therapy, Immunotherapy, Neoadjuvant Systemic Therapy, Others], By End-user [Hospitals, Ambulatory Care Centers, Retail Pharmacies, Online Pharmacies, Cancer Research Institutes, Others], By Region, Opportunities and Forecast, 2016-2030F
The global breast cancer market size was valued at USD 30.2 billion in 2022 and is expected to reach USD 56.4 billion in 2030 with a CAGR of 8.1% for the forecast period between 2023 and 2030F.
Home>Industry Reports>Global Breast Cancer Market Assessment, Opportunities and Forecast, 2016-2030F
Global breast cancer market size was valued at USD 30.2 billion in 2022, and is expected to reach USD 56.4 billion in 2030, with a CAGR of 8.1% for the forecast period between 2023 and 2030F. The breast cancer market is expected to grow due to the increasing prevalence of breast cancer across the globe. According to WHO, more than 2.3 million cases of breast cancer occur each year, which makes it the most common cancer among adults. The surge in the prevalence of breast cancer can be attributed to inherited mutations in genes like BRAC1 and BRAC2, hormonal and lifestyle changes. Adoption of several advanced technologies, like artificial intelligence and machine learning algorithms, in cancer diagnosis and treatment is promising better outcomes for breast cancer in the future, fostering market growth.
Technological advancements in products that help in early detection and better treatment of breast cancer are contributing to the growth of the global breast cancer market. Additionally, a strong pipeline of new drugs, government and stakeholder efforts to eradicate cancer are anticipated to drive the global breast cancer market. However, lack of awareness about breast cancer, higher cost of diagnosis and treatment, and inadequate infrastructure in developing countries are some of the challenges for the global breast cancer market.
In February 2023, Gilead Sciences, Inc. announced that the United States Food and Drug Administration (USFDA) approved Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The drug is meant to be used for patients who have already received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
Increasing Prevalence of Breast Cancer
Breast cancer is the most common cancer in females across the globe. Growing geriatric population, obesity, increased alcohol consumption, radiation exposure, family history of breast cancer, reproductive history, tobacco use, and postmenopausal hormone therapy are some of the factors that increase the risk of breast cancer. Adoption of a sedentary lifestyle is one of the major reasons behind the high prevalence of breast cancer. In recent years, the prevalence of breast cancer has increased significantly without any exception in developed and developing countries. As per sources from American Society of Clinical Oncology, 2,964,197 new female breast cancer cases are expected to occur in 2040, with a 31% increase from the corresponding 2,260,127 cases in 2020. Breast cancer ranks first among all types of cancer with around 12% share by number of cases.
Growing Preference for Targeted Therapy
Targeted therapy is meant to provide specialized treatment for breast cancer, with low adverse effects. It is highly effective as it mainly works on the proteins that cause cancer and promote neoplastic growth, sometimes even better than the effects of chemotherapy. A notable increase in procedures for targeted therapy has been observed in recent years due to increased survival rates, reduced resistance, and fewer side effects. Healthcare professionals are recommending the use of targeted therapy due to increased efficacy and better outcomes in breast cancer treatment.
For instance, in January 2023, Dr. Reddy’s Laboratories Ltd. acquired the trademark for the breast cancer drug, Primcyv from Pfizer Products India Pvt Ltd for use in the Indian market. Primcyv is a targeted therapy for the treatment of breast cancer that targets HR+ and HER2 metastatic breast cancers. Strategic market developments promoting targeted therapy are anticipated to help in the better treatments of breast cancer and further boost the global breast cancer market.
Government Initiatives
Government organizations and agencies are actively promoting the treatment of breast cancer through awareness initiatives, thereby fostering market growth. Government initiatives such as research grants for cancer screening & research and laying favorable policies are fueling market growth. In 2021, National Cancer Institute in the United States invested USD 558.3 million for breast cancer research, and the Australian government invested USD 353.9 million as a part of the 2021-22 budget to support women’s health in the country, including funding for cervical and breast cancer, endometriosis, and reproductive health. In January 2023, the government of the United Kingdom announced a EUR 10 million investment to develop 29 new breast cancer screening units. These units will be dedicated to reducing the burden of breast cancer in the United Kingdom. Such initiatives by the government and funding for breast cancer research, diagnosis, and treatment are anticipated to drive market growth for the global breast cancer market.
Advancement in Oncology
Oncology has witnessed remarkable advancements in the global breast cancer market, transforming cancer diagnosis and treatment. Innovations in molecular diagnostics, liquid biopsies, and next-generation sequencing technologies have improved early detection and personalized treatment approaches. Biomarker identification and companion diagnostic tests have enabled targeted therapies, enhanced patient outcomes, and reduced adverse effects. Additionally, artificial intelligence and machine learning algorithms have played a pivotal role in analyzing complex data, facilitating accurate diagnosis and predicting treatment responses. The rapid growth of this sector can be attributed to the strong inclination of physicians towards in-vitro diagnostics and novel innovations taking place in medical imaging for cancer diagnosis.
In November 2022, Google Health announced a financial agreement with iCAD, a leading market player focused on cancer detection and medical technology development. Through the partnership, iCAD can incorporate Google Health’s mammography AI research model in its products for clinical usage. The advancement will help in better and more precise diagnosis of breast cancers.
Impact of COVID-19
The onset of the COVID-19 pandemic had a negative impact on the global breast cancer market. The market witnessed a significant dip due to preventive restrictions and lockdowns imposed by governments worldwide. Breast screening was reduced significantly which led to low procedure volumes and eventually impacting the market, negatively. Several surgeries and procedures were delayed or postponed due to the risk of contracting the virus in hospital. According to a study published in SAGE, in June 2022, a relative decline from 2019 to 2020 in breast cancer screening was observed, screening mammograms decreased by 44%. Although as an impact of COVID-19 pandemic, the promotion of telehealth, and utilization of artificial intelligence and machine learning created opportunity for several health-tech startups to develop innovative solutions for early diagnosis and prediction of breast cancer. Thus, the overall COVID-19 pandemic negatively affected the screening and treatment rate of breast cancer, however contributed to technological advancements.
Global Breast Cancer Market: Report Scope
“Breast Cancer Market Assessment, Opportunities and Forecast, 2016-2030F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative & quantitative assessment of the current state of the global breast cancer market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, COVID-19 impact, opportunities, and forecast between 2023 and 2030F. Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.
In this report, global breast cancer market has been segmented into the following categories:
1. By Type
1.1. Ductal Carcinoma In Situ (DCIS)
1.2. Invasive Ductal Carcinoma (IDC)
1.3. Lobular Carcinoma In Situ (LCIS)
1.4. Invasive Lobular Cancer (ILC)
1.5. Triple Negative Breast Cancer
1.6. Inflammatory Breast Cancer (IBC)
1.7. Metastatic Breast Cancer
1.8. Breast Cancer During Pregnancy
1.9. Other Types
2. By Treatment Type
2.1. Surgery
2.2. Radiation therapy
2.3. Chemotherapy
2.4. Hormonal therapy
2.4.1.Selective Estrogen Receptor Modulators
2.4.2.Aromatase Inhibitors
2.4.3.Estrogen Receptor Downregulators
2.5. Targeted Therapy
2.5.1.Abemaciclib
2.5.2.Adotrastuzumab Emtansine
2.5.3.Everolimus
2.5.4.Trastuzumab
2.5.5.Ribociclib
2.5.6.Palbocicib
2.5.7.Pertuzumab
2.5.8.Olaparib
2.5.9.Others
2.7. Neoadjuvant Systemic Therapy
2.8. Other
3.1. Hospitals
3.2. Ambulatory Care Centers
3.3. Retail Pharmacies
3.4. Online Pharmacies
3.5. Cancer Research Institutes
3.6. Others
4. By Region
4.1. North America
4.2. Europe
4.3. Asia-Pacific
4.4. South America
4.5. Middle East & Africa
Key Players Landscape and Outlook
Market players are using different strategies to broaden their product offerings and provide their users with access to a vast array of innovative and innovative products. To capture market share, organizations are diversifying their product offerings. To strengthen their market position, industry players use various growth strategies, such as partnerships, mergers and acquisitions, product launches, and manufacturing of new products.
In May 2022, Genentech launched a new combinational drug PHESGO – a combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase for breast cancer patients. The drug is expected to reduce the treatment cost by 20%.
Key Players Operating in the Global Breast Cancer Market are:
· Merck & Co
· Bristol Myers Squibb
· Kyowa Kirin
· Eisai Co., Ltd.
· Sanofi
· Pfizer Inc
· AstraZeneca
· Novartis AG
· Eli Lilly and Company
· Genentech
Markets and Data reports answer the following questions:
• What is the current and future market size of the product/service in question globally or specific to different countries?
• How are the markets divided into different product/service segments and the market size and growth of each segment?
• What is the market potential of different product segments and their investment case?
• How are the markets predicted to develop in the future and what factors will drive or inhibit growth?
• What is the business environment and regulatory landscape specific to the product/service?
If you can't find what you're searching for or have any custom requirements for global breast cancer market, you may approach our team at info@marketsandata.com.
Table of Contents
1. Research Methodology
2. Project Scope & Definitions
3. Impact of COVID-19 on the Global Breast Cancer Market
4. Executive Summary
5. Global Breast Cancer Market Outlook, 2016-2030F
1.1. Market Size & Forecast
1.1.1.By Value
1.1.2.By Volume
1.2. By Type
1.2.1.Ductal Carcinoma In Situ (DCIS)
1.2.2.Invasive Ductal Carcinoma (IDC)
1.2.3.Lobular Carcinoma In Situ (LCIS)
1.2.4.Invasive Lobular Cancer (ILC)
1.2.5.Triple Negative Breast Cancer
1.2.6.Inflammatory Breast Cancer (IBC)
1.2.7.Metastatic Breast Cancer
1.2.8.Breast Cancer During Pregnancy
1.2.9.Other Types
1.3. By Treatment Type
1.3.1.Surgery
1.3.2.Radiation therapy
1.3.3.Chemotherapy
1.3.4.Hormonal therapy
1.3.4.1. Selective Estrogen Receptor Modulators
1.3.4.2. Aromatase Inhibitors
1.3.4.3. Estrogen Receptor Downregulators
1.3.5.Targeted Therapy
1.3.5.1. Abemaciclib
1.3.5.2. Adotrastuzumab Emtansine
1.3.5.3. Everolimus
1.3.5.4. Trastuzumab
1.3.5.5. Ribociclib
1.3.5.6. Palbocicib
1.3.5.7. Pertuzumab
1.3.5.8. Olaparib
1.3.5.9. Others
1.3.6.Immunotherapy
1.3.7.Neoadjuvant systemic therapy
1.3.8.Other
1.4. By End-user
1.4.1.Cancer Research Institutes
1.4.2.Hospitals
1.4.3.Ambulatory Care Centers
1.4.4.Others
1.5. By Region
1.5.1.North America
1.5.2.Europe
1.5.3.Asia-Pacific
1.5.4.South America
1.5.5.Middle East & Africa
1.6. By Company Market Share (%), 2022
6. Global Breast Cancer Market Outlook, By Region, 2016-2030
6.1. North America*
6.1.1.Market Size & Forecast
6.1.1.1. By Value
6.1.1.2. By Volume
6.1.2.By Type
6.1.2.1. Ductal Carcinoma In Situ (DCIS)
6.1.2.2. Invasive Ductal Carcinoma (IDC)
6.1.2.3. Lobular Carcinoma In Situ (LCIS)
6.1.2.4. Invasive Lobular Cancer (ILC)
6.1.2.5. Triple Negative Breast Cancer
6.1.2.6. Inflammatory Breast Cancer (IBC)
6.1.2.7. Metastatic Breast Cancer
6.1.2.8. Breast Cancer During Pregnancy
6.1.2.9. Other Types
6.1.3.By Treatment Type
6.1.3.1. Surgery
6.1.3.2. Radiation therapy
6.1.3.3. Chemotherapy
6.1.3.4. Hormonal therapy
6.1.3.4.1. Selective Estrogen Receptor Modulators
6.1.3.4.2. Aromatase Inhibitors
6.1.3.4.3. Estrogen Receptor Downregulators
6.1.3.5. Targeted Therapy
6.1.3.5.1. Abemaciclib
6.1.3.5.2. Adotrastuzumab Emtansine
6.1.3.5.3. Everolimus
6.1.3.5.4. Trastuzumab
6.1.3.5.5. Ribociclib
6.1.3.5.6. Palbocicib
6.1.3.5.7. Pertuzumab
6.1.3.5.8. Olaparib
6.1.3.5.9. Others
6.1.3.6. Immunotherapy
6.1.3.7. Neoadjuvant systemic therapy
6.1.3.8. Other
6.1.4.By End-user
6.1.4.1. Cancer Research Institutes
6.1.4.2. Hospitals
6.1.4.3. Retail Pharmacies
6.1.4.4. Online Pharmacies
6.1.4.5. Ambulatory Care Centers
6.1.4.6. Others
6.1.5. United States*
6.1.5.1. Market Size & Forecast
6.1.5.1.1. By Value
6.1.5.1.2. By Volume
6.1.5.2. By Type
6.1.5.2.1. Ductal Carcinoma In Situ (DCIS)
6.1.5.2.2. Invasive Ductal Carcinoma (IDC)
6.1.5.2.3. Lobular Carcinoma In Situ (LCIS)
6.1.5.2.4. Invasive Lobular Cancer (ILC)
6.1.5.2.5. Triple Negative Breast Cancer
6.1.5.2.6. Inflammatory Breast Cancer (IBC)
6.1.5.2.7. Metastatic Breast Cancer
6.1.5.2.8. Breast Cancer During Pregnancy
6.1.5.2.9. Other Types
6.1.5.3. By Treatment Type
6.1.5.3.1. Surgery
6.1.5.3.2. Radiation therapy
6.1.5.3.3. Chemotherapy
6.1.5.3.4. Hormonal therapy
6.1.5.3.4.1. Selective Estrogen Receptor Modulators
6.1.5.3.4.2. Aromatase Inhibitors
6.1.5.3.4.3. Estrogen Receptor Downregulators
6.1.5.3.5. Targeted Therapy
6.1.5.3.5.1. Abemaciclib
6.1.5.3.5.2. Adotrastuzumab Emtansine
6.1.5.3.5.3. Everolimus
6.1.5.3.5.4. Trastuzumab
6.1.5.3.5.5. Ribociclib
6.1.5.3.5.6. Palbocicib
6.1.5.3.5.7. Pertuzumab
6.1.5.3.5.8. Olaparib
6.1.5.3.5.9. Others
6.1.5.3.6. Immunotherapy
6.1.5.3.7. Neoadjuvant systemic therapy
6.1.5.3.8. Other
6.1.5.4. By End-user
6.1.5.4.1. Cancer Research Institutes
6.1.5.4.2. Hospitals
6.1.5.4.3. Retail Pharmacies
6.1.5.4.4. Online Pharmacies
6.1.5.4.5. Ambulatory Care Centers
6.1.5.4.6. Others
6.1.6.Canada
6.1.7.Mexico
*All segments will be provided for all regions and countries covered
6.2. Europe
6.2.1.Germany
6.2.2.France
6.2.3.Italy
6.2.4.United Kingdom
6.2.5.Russia
6.2.6.Netherlands
6.2.7.Spain
6.2.8.Turkey
6.2.9.Poland
6.3. South America
6.3.1.Brazil
6.3.2.Argentina
6.4. Asia-Pacific
6.4.1.India
6.4.2.China
6.4.3.Japan
6.4.4.Australia
6.4.5.Vietnam
6.4.6.South Korea
6.4.7.Indonesia
6.4.8.Philippines
6.5. Middle East & Africa
6.5.1.Saudi Arabia
6.5.2.UAE
6.5.3.South Africa
7. Market Mapping, 2022
7.1. By Type
7.2. By Treatment Type
7.3. By End-user
7.4. By Region
8. Macro Environment and Industry Structure
8.1. Supply Demand Analysis
8.2. Import Export Analysis – Volume and Value
8.3. Supply/Value Chain Analysis
8.4. PESTEL Analysis
8.4.1.Political Factors
8.4.2.Economic System
8.4.3.Social Implications
8.4.4.Technological Advancements
8.4.5.Environmental Impacts
8.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
8.5. Porter’s Five Forces Analysis
8.5.1.Supplier Power
8.5.2.Buyer Power
8.5.3.Substitution Threat
8.5.4.Threat from New Entrant
8.5.5.Competitive Rivalry
9. Market Dynamics
9.1. Growth Drivers
9.2. Growth Inhibitors (Challenges, Restraints)
10. Regulatory Framework and Innovation
10.1. Clinical Trials
10.2. Patent Landscape
10.3. Regulatory Approvals
10.4. Innovations/Emerging Technologies
11. Key Players Landscape
11.1. Competition Matrix of Top Five Market Leaders
11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2022)
11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
11.4. SWOT Analysis (For Five Market Players)
11.5. Patent Analysis (If Applicable)
12. Pricing Analysis
13. Case Studies
14. Key Players Outlook
14.1. Merck & Co
14.1.1. Company Details
14.1.2. Key Management Personnel
14.1.3. Products & Services
14.1.4. Financials (As reported)
14.1.5. Key Market Focus & Geographical Presence
14.1.6. Recent Developments
14.3. Kyowa Kirin
14.4. Eisai Co., Ltd.
14.5. Sanofi
14.6. Pfizer Inc
14.7. AstraZeneca
14.8. Novartis AG
14.9. Eli Lilly and Company
14.10. Genentech
*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work
15. Strategic Recommendations
16. About Us & Disclaimer
List of Figures: Global Breast Cancer Market
Figure 1. Global Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 2. Global Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 3. Global Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 4. Global Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 5. Global Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 6. Global Breast Cancer Market Share, By Region, in USD Billion, 2016-2030F
Figure 7. North America Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 8. North America Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 9. North America Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 10. North America Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 11. North America Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 12. North America Breast Cancer Market Share, By Country, in USD Billion, 2016-2030F
Figure 13. United States Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 14. United States Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 15. United States Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 16. United States Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 17. United States Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 18. Canada Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 19. Canada Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 20. Canada Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 21. Canada Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 22. Canada Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 23. Mexico Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 24. Mexico Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 25. Mexico Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 26. Mexico Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 27. Mexico Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 28. Europe Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 29. Europe Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 30. Europe Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 31. Europe Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 32. Europe Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 33. Europe Breast Cancer Market Share, By Country, in USD Billion, 2016-2030F
Figure 34. Germany Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 35. Germany Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 36. Germany Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 37. Germany Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 38. Germany Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 39. France Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 40. France Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 41. France Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 42. France Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 43. France Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 44. Italy Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 45. Italy Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 46. Italy Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 47. Italy Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 48. Italy Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 49. United Kingdom Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 50. United Kingdom Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 51. United Kingdom Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 52. United Kingdom Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 53. United Kingdom Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 54. Russia Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 55. Russia Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 56. Russia Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 57. Russia Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 58. Russia Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 59. Netherlands Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 60. Netherlands Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 61. Netherlands Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 62. Netherlands Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 63. Netherlands Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 64. Spain Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 65. Spain Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 66. Spain Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 67. Spain Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 68. Spain Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 69. Turkey Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 70. Turkey Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 71. Turkey Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 72. Turkey Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 73. Turkey Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 74. Poland Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 75. Poland Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 76. Poland Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 77. Poland Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 78. Poland Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 79. South America Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 80. South America Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 81. South America Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 82. South America Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 83. South America Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 84. South America Breast Cancer Market Share, By Country, in USD Billion, 2016-2030F
Figure 85. Brazil Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 86. Brazil Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 87. Brazil Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 88. Brazil Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 89. Brazil Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 90. Argentina Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 91. Argentina Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 92. Argentina Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 93. Argentina Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 94. Argentina Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 95. Asia-Pacific Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 96. Asia-Pacific Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 97. Asia-Pacific Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 98. Asia-Pacific Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 99. Asia-Pacific Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 100. Asia-Pacific Breast Cancer Market Share, By Country, in USD Billion, 2016-2030F
Figure 101. India Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 102. India Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 103. India Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 104. India Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 105. India Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 106. China Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 107. China Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 108. China Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 109. China Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 110. China Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 111. Japan Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 112. Japan Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 113. Japan Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 114. Japan Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 115. Japan Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 116. Australia Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 117. Australia Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 118. Australia Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 119. Australia Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 120. Australia Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 121. Vietnam Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 122. Vietnam Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 123. Vietnam Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 124. Vietnam Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 125. Vietnam Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 126. South Korea Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 127. South Korea Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 128. South Korea Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 129. South Korea Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 130. South Korea Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 131. Indonesia Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 132. Indonesia Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 133. Indonesia Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 134. Indonesia Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 135. Indonesia Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 136. Philippines Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 137. Philippines Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 138. Philippines Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 139. Philippines Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 140. Philippines Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 141. Middle East & Africa Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 142. Middle East & Africa Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 143. Middle East & Africa Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 144. Middle East & Africa Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 145. Middle East & Africa Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 146. Middle East & Africa Breast Cancer Market Share, By Country, in USD Billion, 2016-2030F
Figure 147. Saudi Arabia Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 148. Saudi Arabia Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 149. Saudi Arabia Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 150. Saudi Arabia Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 151. Saudi Arabia Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 152. UAE Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 153. UAE Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 154. UAE Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 155. UAE Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 156. UAE Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 157. South Africa Breast Cancer Market, By Value, in USD Billion, 2016-2030F
Figure 158. South Africa Breast Cancer Market, By Volume, in Thousands, 2016-2030F
Figure 159. South Africa Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
Figure 160. South Africa Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
Figure 161. South Africa Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
Figure 162. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2022
Figure 163. By Treatment Type Map-Market Size (USD Billion) & Growth Rate (%), 2022
Figure 164. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2022
Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2022
List of Tables: Global Breast Cancer Market
Table 1. Pricing Pivot and Marginal Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects
Frequently Asked Questions
What are the regions covered in the final report for global breast cancer market?
Who are the key players operating in the global breast cancer market?
What are the major drivers influencing the growth of global breast cancer market?
What is the market size and growth rate of global breast cancer market?
See Related Reports
Global Coffee Market Assessment, Opportunities and Forecast, 2017-2031F
Global coffee market is expected to experience growth due to consumers’ increasing preference for organic and premium coffee that offers freshness, superior quality of beans and roasts, and unique flavor profile. Additionally, the product innovation,....Read More
Published on
July 2024
4,500
Global Home Theater System Market Assessment, Opportunities and Forecast, 2017-2031F
Global home theater system market is expected to experience growth due to technological advancements, increasing disposable incomes, rising demand for high-definition content, integration with smart home systems, and the surge in streaming services p....Read More
Published on
July 2024
4,500
Global Baby Food Market Assessment, Opportunities and Forecast, 2017-2031F
Global baby food market is expected to experience growth due to factors such as consumers’ increasing awareness of the nutrients which are essential for babies development and introduction of wide variety of baby foods in the market from milk powders....Read More
Published on
July 2024
4,500
Global Isoflavones Market Assessment, Opportunities and Forecast, 2017-2031F
Global isoflavones market is expected to experience growth due to increasing consumer health awareness, rising demand for functional foods and nutraceuticals, advancements in extraction technologies, and expanding applications in cosmetics, pharmaceu....Read More
Published on
July 2024
4,500
Purchase Options
USD ($)
i
3,000
i
4,500
i
5,700
i
8,200
Tired of Searching?
Looking for Customization?
Some other doubt?
Need insights from a cohort?
REACH US
